We help founders transform industries.

Venture investment in technology and healthcare

GLOBAL MULTI-STAGE INVESTOR, WORLD-CLASS NETWORK

Approach

Sixty Degree Capital invests in companies creating meaningful change in their industries, across sectors (software, digital infrastructure, healthcare, biotech) and across stages (as early as Series A, as late as pre-IPO).

Advantage

We have a world-class network, specialized in-house expertise, and relationships with marquee investors. This differentiation enables us to support our portfolio companies and generate exceptional returns for our investors.

Our Portfolio

Antios Therapeutics logo
Aqua logo in multicolor with no background
Arcellx logo in multicolor with no background
Arctic Wolf Logo on a Transparent Background One
Bionaut logo in multicolor with no background
Cato networks logo in multicolor with no background
Cincor logo
Clearcover logo
Data Grail Logo on a Transparent Background
Docker logo in multicolor with no background
Engage Therapeutics logo
Everly Health logo
GrubMarket logo
Inspirna logo
Korro
Libra Therapeutics logo
Lime logo
Macrometa logo
Miovision logo
Monte Rosa Therapeutics
Navan networks logo in black color with no background
Nextpointtx logo in black color with no background
Northern Biologics logo
Paper space logo in black color with no background
Pipeline logo
Pragma logo
Radius Agent and Realty logo
Reflexion logo
Schrodinger logo
Tact.ai logo
Tknife Therapeutics logo
TransThera logo
Turnstone Biologics logo
Veem logo
Aqua logo in multicolor with no background
Arctic Wolf Logo on a Transparent Background
Cato networks logo in multicolor with no background
Data Grail Logo on a Transparent Background
Docker logo in multicolor with no background
Everly Health logo
Lime logo
Macrometa logo
Miovision logo
Navan networks logo in black color with no background
Paper space logo in black color with no background
Pragma logo
Radius Agent and Realty logo
Schrodinger logo
Tact.ai logo
Veem logo
Bionaut logo in multicolor with no background
Cincor logo
Engage Therapeutics logo
Inspirna logo
Korro
Libra Therapeutics logo
Nextpointtx logo in black color with no background
Reflexion logo
Schrodinger logo
Tknife Therapeutics logo
TransThera logo
Turnstone Biologics logo
Cincor logo
Engage Therapeutics logo
Monte Rosa Therapeutics
Northern Biologics logo
Paper space logo in black color with no background
Schrodinger logo

Our Team

Blog/News

News

T-knife Therapeutics Announces $110 Million Series B Financing to Advance Pipeline of T-cell Receptor Therapies

– Plan to initiate the IMAG1NE Phase 1/2 clinical study of TK-8001, a TCR-T cell therapy for MAGE-A1 positive solid tumors, in 2021 August 02, 2021 08:00 ET| Source: T-knife Therapeutics SAN FRANCISCO and BERLIN, Aug. 02, 2021 (GLOBE NEWSWIRE) — T-knife Therapeutics, Inc., a next-generation T-cell receptor company developing a pipeline of innovative therapeutics for…
Read More

Everside Health Announces $164 Million in Growth Equity Funding from NEA and New Investors

Existing investors NEA, Oak HC/FT and Alta Partners, and new investors, including Endeavor Catalyst, joined the round Funding will accelerate growth, enhance Everside’s technology stack to facilitate predictive, whole-patient care, and support potential M&A opportunities DENVER, July 25, 2022 /PRNewswire/ — Everside Health, LLC, a leading national direct primary care provider, today announced that it has raised $164 million in growth equity funding. Longstanding investor…
Read More

KITE AND ARCELLX ANNOUNCE STRATEGIC COLLABORATION TO CO-DEVELOP AND CO-COMMERCIALIZE LATE-STAGE CLINICAL CART-DDBCMA IN MULTIPLE MYELOMA

— Collaboration Leverages Expertise Across Both Companies, Including Kite’s Global Cell Therapy Leadership and Industry Leading Reliable Manufacturing — SANTA MONICA, Calif. & REDWOOD CITY, Calif.–(BUSINESS WIRE)– Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced a global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for…
Read More

CinCor Pharma to be Acquired by AstraZeneca

January 09, 2023 02:05 ET| Source: CinCor Pharma IncFollow WALTHAM, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) — CinCor Pharma, Inc. (NASDAQ: CINC) today announced that it has entered into a definitive agreement with AstraZeneca under which AstraZeneca has agreed to acquire CinCor. Marc de Garidel, Chief Executive Officer at CinCor, said: “We are excited about the…
Read More

RefleXion Receives FDA Clearance for SCINTIX Biology-Guided Radiotherapy; Cutting-edge Treatment Applicable for Early and Late-stage Cancers

HAYWARD, Calif.–(BUSINESS WIRE)–RefleXion Medical, a therapeutic oncology company, today announced the U.S. Food and Drug Administration (FDA) has granted the first marketing clearance for its SCINTIX™ biology-guided radiotherapy, a cutting-edge treatment applicable for early and late-stage cancers. The company will host a live-stream event featuring both its co-founder and CEO discussing the breakthrough significance of SCINTIX…
Read More

NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs

Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells January 10, 2023 09:00 AM Eastern Standard Time CAMBRIDGE, Mass. & LEVERKUSEN, Germany–(BUSINESS WIRE)–NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps…
Read More

Send us Message

  • This field is for validation purposes and should be left unchanged.